Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals
Open Access
- 1 September 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 56 (4) , 738-744
- https://doi.org/10.1093/jac/dki308
Abstract
Objectives: The site of action of efavirenz is inside HIV-infected cells. Measurement of intracellular (IC) concentrations of efavirenz may therefore provide further understanding of therapeutic failure, especially where virological rebound occurs despite adequate plasma levels, and a lack of detectable viral resistance. Here, we determined IC and plasma pharmacokinetics of efavirenz and their relationship with plasma protein binding and P-glycoprotein (P-gp, an active drug efflux transporter) expression. Patients and methods: Venous blood samples from 10 HIV-infected patients receiving efavirenz (600 mg once a day plus two nucleoside reverse transcriptase inhibitors) were collected over the 24 h dosing interval. Plasma and peripheral blood mononuclear cells (PBMCs) were isolated. Plasma protein bound and unbound efavirenz were separated using ultrafiltration. IC (or cell-associated), total plasma and unbound plasma efavirenz levels were quantified using HPLC-UV. P-gp expression was measured by flow cytometry. Area under the concentration-time curves (AUC0–24) were then calculated using non-compartmental analyses and the IC accumulation expressed as a ratio of IC to plasma AUC0–24. Results: The median (range) % unbound and IC accumulation ratio was 0.6% (0.4–1.5%) and 1.3 (0.7–3.3), respectively. There was a linear relationship between IC and total AUC0–24 (r2 = 0.59, P = 0.01) but not unbound AUC0–24 (r2 = 0.13, P = 0.75). An inverse correlation between IC AUC0–24 and % unbound was observed (r2 = 41, P = 0.05). There was no relationship between IC AUC0–24 and P-gp expression on the cell surface (r2 < 0.01, P = 0.98). Conclusions: There was a direct relationship between % bound efavirenz in plasma and IC accumulation implying that the IC accumulation of efavirenz is related to binding to IC proteins or other cellular constituents. Studies investigating the unbound concentration of antiretrovirals inside the cell are now required.Keywords
This publication has 21 references indexed in Scilit:
- The intracellular pharmacology of antiretroviral protease inhibitorsJournal of Antimicrobial Chemotherapy, 2004
- Intracellular and Plasma Pharmacokinetics of Saquinavir-Ritonavir, Administered at 1,600/100 Milligrams Once Daily in Human Immunodeficiency Virus-Infected PatientsAntimicrobial Agents and Chemotherapy, 2004
- Roundtable Report: Importance of Antiretroviral Drug Concentrations in Sanctuary Sites and Viral ReservoirsAIDS Research and Human Retroviruses, 2003
- Intracellular Concentration of Protease Inhibitors in HIV-1--Infected Patients: Correlation with MDR-1 Gene Expression and Low Dose of RitonavirHIV Research & Clinical Practice, 2002
- Intracellular Accumulation of Human Immunodeficiency Virus Protease InhibitorsAntimicrobial Agents and Chemotherapy, 2002
- P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?AIDS, 2001
- Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication.Proceedings of the National Academy of Sciences, 1993
- Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody.Proceedings of the National Academy of Sciences, 1992
- Accurate, Wide-Range, Automated, High-Performance Liquid Chromatographic Method for the Estimation of Octanol/ Water Partition Coefficients II: Equilibrium in Partition Coefficient Measurements, Additivity of Substituent Constants, and Correlation of Biological DataJournal of Pharmaceutical Sciences, 1984
- Solubility and Partitioning VI: Octanol Solubility and Octanol–Water Partition CoefficientsJournal of Pharmaceutical Sciences, 1983